Springer - Immunogenicity of Biopharmaceuticals, Vol VIII

This specialized volume from Springer addresses a critical challenge in biotechnology: the potential for immune responses to biopharmaceutical products. When the human body identifies a drug as a foreign substance, it can develop antibodies that may cause complications. While some antibodies are relatively harmless, others can cross-react with endogenous compounds, leading to autoimmunogenicity. This book provides a comprehensive look at these risks, a topic that has not been fully covered in previous literature. It examines the importance of monitoring immunogenicity, especially following significant regulatory attention triggered by adverse experiences with products like Janssen-Ortho's Eprex. This text serves as a vital resource for understanding how the body reacts to modern biological drugs and the implications for pharmaceutical safety and regulation.